Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA plans the imminent release of a white paper outlining a new national medical device post-market surveillance strategy in the lead up to public meetings Sept.10-13. More regulatory news below.

You may also be interested in...



Regulatory News In Brief

FDA issues final rule on good manufacturing practices for combination products. Rule withdrawn on scientific misconduct policy. More regulatory news.

FDA Unveils Plan To Strengthen Device Post-Market Surveillance

Combining new techniques with improvements to current tools, the strategy aims for "near real-time" post-market surveillance.

Final FDA Bill: Device Provisions

Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel